節足動物媒介性ウイルス感染症検査市場：検査タイプ別、エンドユーザー別-2025～2030年の世界予測

節足動物媒介性ウイルス感染症検査市場は、2023年に109億9,000万米ドルと評価され、2024年には121億8,000万米ドルに達すると予測され、CAGR 10.88％で成長し、2030年には226億6,000万米ドルに達すると予測されています。

節足動物媒介性ウイルス感染症検査の対象範囲には、蚊、ダニ、ノミなどの節足動物を通じて感染するウイルス感染の検出を目的とした診断手順が含まれます。これらの感染症には、ジカウイルス、デング熱、チクングニア、西ナイルウイルスなどが含まれます。このような検査の必要性は、タイムリーな医療介入を促進し、発生を制御し、公衆衛生施策を導くために、迅速かつ正確な診断の必要性から生じる。最終用途は公衆衛生機関、研究機関、医療施設に及び、検査室、病院、診断センターに適用されます。市場の成長は、世界の旅行者の増加、都市化、気候変動、節足動物媒介性疾患に対する意識の高まりなどの要因に影響され、先進的検査手法に対する需要の高まりにつながっています。PCRや次世代シーケンシングを含む分子診断の技術的進歩は、潜在的なビジネス機会をもたらします。推奨事項としては、費用対効果が高く、迅速で高精度の検査ソリューション、特に遠隔地や資源不足の地域でのアクセスを民主化できるポイントオブケア診断法の開発のための研究開発への投資が挙げられます。

市場に影響を与える課題には、規制のハードル、先進的検査技術の高コスト、新興国地域の限られたインフラなどがあります。さらに、薬剤耐性ウイルス株の出現や、地域によって異なる有病率が複雑さを増しています。また、検査を実施・解釈する熟練した専門家の不足も、市場の成長を抑制する可能性があります。マルチプレックス検査プラットフォームや、データ分析と人工知能を統合したデジタルソリューションの革新は、新たな研究の道を開く可能性があります。資金調達や支援のための政府・非政府組織との連携は、参入障壁を緩和し、裾野を広げる可能性があります。市場洞察によれば、予防対策に関して医療専門家と一般市民を教育するための協調的な取り組みが急務であることが示唆されます。市場は本質的にダイナミックであり、節足動物媒介性感染症の季節的・地理的変動に左右されます。この市場情勢において成長機会を捉えつつ課題に対処するには、従来の診断法と新たな技術を組み合わせた積極的なアプローチが不可欠です。

市場力学：急速に進化する節足動物媒介性ウイルス感染症検査市場の主要市場洞察を公開

節足動物媒介性ウイルス感染症検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 節足動物媒介性ウイルス感染の増加
  • 節足動物媒介性ウイルス診断法の改善
  • アルボウイルス感染症に関する政府の取り組みと啓発キャンペーン
• 市場抑制要因
  • 節足動物媒介性ウイルス感染症診断キットの製品回収の発生
• 市場機会
  • ELISAベースの検査診断の受け入れ拡大
  • 検査法の技術的進歩
• 市場課題
  • 研究開発やワクチン開発のためのアルボウイルス動物モデル開発の難しさ

ポーターのファイブフォース：節足動物媒介性ウイルス感染症検査市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：節足動物媒介性ウイルス感染症検査市場における外部からの影響の把握

外部マクロ環境要因は、節足動物媒介性ウイルス感染症検査市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：節足動物媒介性ウイルス感染症検査市場における競合情勢の把握

節足動物媒介性ウイルス感染症検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：節足動物媒介性ウイルス感染症検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、節足動物媒介性ウイルス感染症検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：節足動物媒介性ウイルス感染症検査市場における成功への道筋を描く

節足動物媒介性ウイルス感染症検査市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 節足動物媒介性ウイルス感染の増加
    • 節足動物媒介性ウイルス診断の改善
    • アルボウイルス感染に関する政府の取り組みと啓発キャンペーン
  • 抑制要因
    • 節足動物媒介性ウイルス感染症診断キットの製品回収事例
  • 機会
    • ELISAベースの検査診断の普及
    • 検査方法の技術的進歩
  • 課題
    • 研究とワクチン開発のためのアルボウイルス動物モデルの開発の難しさ
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 節足動物媒介性ウイルス感染症検査市場：検査タイプ別

• イントロダクション
• 文化検査
• 免疫検査
• 分子検査

第7章 節足動物媒介性ウイルス感染症検査市場：エンドユーザー別

• イントロダクション
• 診断センター
• 病院
• 研究センター

第8章 南北アメリカの節足動物媒介性ウイルス感染症検査市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋の節足動物媒介性ウイルス感染症検査市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの節足動物媒介性ウイルス感染症検査市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Abnova Corporation
• ACROBiosystems
• AdvaCare Pharma
• ARUP Laboratories
• Bio Lab Diagnostics（I）Private Limited
• Bio-Rad Laboratories, Inc.
• Bio-Techne
• BIOGENIX INC. PVT. LTD.
• bioMerieux SA
• Chembio Diagnostics, Inc.
• Clongen Laboratories, LLC
• Coppe Laboratories
• EIKEN CHEMICAL Co., Ltd.
• Elabscience BIoTechnology Inc.
• EUROIMMUN AG by PerkinElmer Inc.
• F. Hoffmann-La Roche Ltd
• Hologic, Inc.
• InBios International, Inc.
• J Mitra & Co Ltd
• Kephera Diagnostics
• Merck KGaA
• Quest Diagnostics Incorporated
• Sonora Quest Laboratories LLC
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET RESEARCH PROCESS
• FIGURE 2. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CULTURAL TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 21. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 23. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 25. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 33. AUSTRALIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 35. CHINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. INDIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 37. INDIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 39. INDONESIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 41. JAPAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 43. MALAYSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 45. PHILIPPINES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 47. SINGAPORE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 49. SOUTH KOREA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 51. TAIWAN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 53. THAILAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 55. VIETNAM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 60. DENMARK ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 62. EGYPT ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 64. FINLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 66. FRANCE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 68. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 70. ISRAEL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. ITALY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 72. ITALY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 74. NETHERLANDS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 76. NIGERIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 78. NORWAY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. POLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 80. POLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. QATAR ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 82. QATAR ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 84. RUSSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SAUDI ARABIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 90. SPAIN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 92. SWEDEN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 94. SWITZERLAND ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 96. TURKEY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 98. UNITED ARAB EMIRATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 100. UNITED KINGDOM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 102. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Arthropod-borne Viral Infections Testing Market was valued at USD 10.99 billion in 2023, expected to reach USD 12.18 billion in 2024, and is projected to grow at a CAGR of 10.88%, to USD 22.66 billion by 2030.

The scope of Arthropod-borne Viral Infections Testing encompasses diagnostic procedures aimed at detecting viral infections transmitted through arthropods such as mosquitoes, ticks, and fleas. These infections include Zika virus, dengue fever, chikungunya, West Nile virus, and others. The necessity for such testing arises from the need for rapid and accurate diagnosis to facilitate timely medical interventions, control outbreaks, and guide public health policies. Applications extend to laboratories, hospitals, and diagnostic centers, with end-use spanning public health agencies, research institutes, and healthcare facilities. Market growth is influenced by factors such as the rise in global travel, urbanization, climate change, and increasing awareness about arthropod-borne diseases, leading to higher demand for advanced testing methodologies. Technological advancement in molecular diagnostics, including PCR and next-generation sequencing, presents potential opportunities. Recommendations include investing in R&D for developing cost-effective, rapid, and high-accuracy testing solutions, especially point-of-care diagnostics that could democratize access in remote or under-resourced areas.

Challenges impacting the market include regulatory hurdles, high costs of advanced testing technology, and limited infrastructure in developing regions. Furthermore, the emergence of drug-resistant virus strains and variable prevalence rates across different geographies add complexity. Limitations in the availability of skilled professionals to perform and interpret tests may also restrain market growth. Innovations in multiplex testing platforms and digital solutions that integrate data analytics and artificial intelligence could open new research avenues. Collaborations with governmental and non-governmental organizations for funding and support can ease entry barriers and expand reach. Market insights suggest an urgent need for concerted efforts in educating healthcare professionals and the general populace regarding preventive measures. The market is inherently dynamic, driven by seasonal and geographical variations in arthropod-borne infections. A proactive approach, combining traditional diagnostic methods with emerging technologies, will be crucial for addressing the challenges while seizing growth opportunities in this market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Arthropod-borne Viral Infections Testing Market

The Arthropod-borne Viral Infections Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing arthropod-borne viral infections
  • Improvements in arthropod-borne viral diagnostics
  • Government initiatives and awareness campaigns regarding arboviral infections
• Market Restraints
  • Product recall incidences of arthropod-borne viral infections diagnostic kits
• Market Opportunities
  • Rising acceptance of ELISA-based test diagnostics
  • Technological advancements in testing methods
• Market Challenges
  • Difficulties in developing arbovirus animal models for research study and vaccine development

Porter's Five Forces: A Strategic Tool for Navigating the Arthropod-borne Viral Infections Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Arthropod-borne Viral Infections Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Arthropod-borne Viral Infections Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Arthropod-borne Viral Infections Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Arthropod-borne Viral Infections Testing Market

A detailed market share analysis in the Arthropod-borne Viral Infections Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Arthropod-borne Viral Infections Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Arthropod-borne Viral Infections Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Arthropod-borne Viral Infections Testing Market

A strategic analysis of the Arthropod-borne Viral Infections Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Arthropod-borne Viral Infections Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abnova Corporation, ACROBiosystems, AdvaCare Pharma, ARUP Laboratories, Bio Lab Diagnostics (I) Private Limited, Bio-Rad Laboratories, Inc., Bio-Techne, BIOGENIX INC. PVT. LTD., bioMerieux SA, Chembio Diagnostics, Inc., Clongen Laboratories, LLC, Coppe Laboratories, EIKEN CHEMICAL Co., Ltd., Elabscience Biotechnology Inc., EUROIMMUN AG by PerkinElmer Inc., F. Hoffmann-La Roche Ltd, Hologic, Inc., InBios International, Inc., J Mitra & Co Ltd, Kephera Diagnostics, Merck KGaA, Quest Diagnostics Incorporated, Sonora Quest Laboratories LLC, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Arthropod-borne Viral Infections Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Test Type, market is studied across Cultural Tests, Immunoassays, and Molecular Tests.
• Based on End-user, market is studied across Diagnostic Centers, Hospitals, and Research Centers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing arthropod-borne viral infections
    • 5.1.1.2. Improvements in arthropod-borne viral diagnostics
    • 5.1.1.3. Government initiatives and awareness campaigns regarding arboviral infections
  • 5.1.2. Restraints
    • 5.1.2.1. Product recall incidences of arthropod-borne viral infections diagnostic kits
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising acceptance of ELISA-based test diagnostics
    • 5.1.3.2. Technological advancements in testing methods
  • 5.1.4. Challenges
    • 5.1.4.1. Difficulties in developing arbovirus animal models for research study and vaccine development
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Arthropod-borne Viral Infections Testing Market, by Test Type

• 6.1. Introduction
• 6.2. Cultural Tests
• 6.3. Immunoassays
• 6.4. Molecular Tests

7. Arthropod-borne Viral Infections Testing Market, by End-user

• 7.1. Introduction
• 7.2. Diagnostic Centers
• 7.3. Hospitals
• 7.4. Research Centers

8. Americas Arthropod-borne Viral Infections Testing Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Arthropod-borne Viral Infections Testing Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Arthropod-borne Viral Infections Testing Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Abnova Corporation
• 3. ACROBiosystems
• 4. AdvaCare Pharma
• 5. ARUP Laboratories
• 6. Bio Lab Diagnostics (I) Private Limited
• 7. Bio-Rad Laboratories, Inc.
• 8. Bio-Techne
• 9. BIOGENIX INC. PVT. LTD.
• 10. bioMerieux SA
• 11. Chembio Diagnostics, Inc.
• 12. Clongen Laboratories, LLC
• 13. Coppe Laboratories
• 14. EIKEN CHEMICAL Co., Ltd.
• 15. Elabscience Biotechnology Inc.
• 16. EUROIMMUN AG by PerkinElmer Inc.
• 17. F. Hoffmann-La Roche Ltd
• 18. Hologic, Inc.
• 19. InBios International, Inc.
• 20. J Mitra & Co Ltd
• 21. Kephera Diagnostics
• 22. Merck KGaA
• 23. Quest Diagnostics Incorporated
• 24. Sonora Quest Laboratories LLC
• 25. Thermo Fisher Scientific Inc.